John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK shares what important chronic lymphocytic leukemia (CLL) trial updates will be coming up at ASH 2020. A number of studies focused on combined ibrutinib plus venetoclax therapy will share results, including the US-based Phase II CAPTIVATE study. He also looks forward to seeing the 5-year MURANO study updates of venetoclax-rituximab in relapsed/refractory CLL, and further data on BTK inhibitors, such as LOXO-305. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.